Breaking News

PPD Names Health Outcomes VP

By Kristin Brooks | March 20, 2014

Pollock to direct health outcomes and evidence-based medicine

Michael Pollock has been appointed vice president of real world outcomes at Pharmaceutical Product Development, LLC (PPD). Mr. Pollock is responsible for directing and enhancing the company’s capabilities in health outcomes and evidence-based medicine to help biopharmaceutical clients optimize market and patient access to novel therapies.
Most recently, Mr. Pollock was president of Reynolds Pollock & Associates, a health outcomes research and market access strategy consulting company. He also held roles as vice president of global health economics at Biogen Idec, vice president of sales and marketing at Elan Pharmaceuticals, vice president of sales and marketing and information services at Oncology Therapeutics Network, a division of Bristol-Myers Squibb, and director and head of worldwide health economics at Glaxo Wellcome.

“PPD is continually strengthening its offerings across the real world outcomes spectrum, and Michael brings a unique background to this role, having held senior positions both in sales and marketing, and in health economics for both large pharmaceutical and biotechnology companies,” said Rob Dow, M.D., PPD’s senior vice president of medical affairs. “He has the knowledge, experience and leadership skills to help grow PPD’s real world outcomes solutions, as we drive value and fuel success for clients.”
PPD tailors real world outcomes studies for clients aimed at providing flexible designs that meet specific objectives, marketplace needs and regulatory requirements in the post-approval environment.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks